MicroRNA-1298-3p inhibits proliferation and invasion of glioma cells by downregulating Nidogen-1.


Journal

Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617

Informations de publication

Date de publication:
30 04 2020
Historique:
received: 16 11 2019
accepted: 29 03 2020
pubmed: 2 5 2020
medline: 26 2 2021
entrez: 2 5 2020
Statut: ppublish

Résumé

Glioma is the most prevalent tumor of the central nervous system. To identify differentially expressed miRNAs (DEMs) in gliomas of different grades, bioinformatics analysis was performed. The DEMs between low-grade gliomas (LGGs) and high-grade gliomas (HGGs) were identified by screening the Gene Expression Omnibus and The Cancer Genome Atlas databases using the LIMMA package. Six overlapping DEMs were identified by comparing LGGs and HGGs. Downregulation of miR-1298-3p correlated with poor overall survival rates in glioma patients. Overexpression of miR-1298-3p induced apoptosis of glioma cells and inhibited glioma cell proliferation, migration, and invasion. The basement membrane protein Nidogen-1 (NID1) was identified as a direct binding target of miR-1298-3p in glioma cells. MiR-1298-3p agonist downregulated the NID1 and vimentin levels, but upregulated the level of E-cadherin in glioma cells. Importantly, overexpression of miR-1298-3p induced apoptosis and reduced tumor growth in a mouse xenograft model of glioma. Our results show that miR-1298-3p functions as a tumor suppressor in glioma cells, and suggest that it might serve as a potential biomarker and therapeutic target in glioma patients.

Identifiants

pubmed: 32355035
doi: 10.18632/aging.103087
pii: 103087
pmc: PMC7244082
doi:

Substances chimiques

MIRN1298 microRNA, human 0
Membrane Glycoproteins 0
MicroRNAs 0
Neoplasm Proteins 0
RNA, Neoplasm 0
nidogen 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7761-7773

Références

Exp Ther Med. 2019 Mar;17(3):2077-2084
pubmed: 30867694
Cancer Cell Int. 2019 Oct 16;19:269
pubmed: 31636512
Eur Rev Med Pharmacol Sci. 2018 Mar;22(6):1672-1679
pubmed: 29630111
Oncol Lett. 2019 Nov;18(5):4659-4666
pubmed: 31611975
Oncol Lett. 2019 Nov;18(5):4882-4890
pubmed: 31611998
Cancer Cell Int. 2019 Oct 11;19:265
pubmed: 31632199
Onco Targets Ther. 2019 Apr 02;12:2451-2463
pubmed: 31040689
Cell. 2004 Aug 6;118(3):277-9
pubmed: 15294153
JAMA Oncol. 2018 Sep 1;4(9):1254-1262
pubmed: 29931168
Pharmacol Res. 2019 Sep;147:104390
pubmed: 31398406
Nat Rev Neurosci. 2018 Jul;19(7):393-403
pubmed: 29777182
J Clin Invest. 2017 Feb 1;127(2):415-426
pubmed: 28145904
Eur Rev Med Pharmacol Sci. 2019 Aug;23(15):6612-6620
pubmed: 31378903
Oncotarget. 2017 May 16;8(20):33110-33121
pubmed: 28416770
Genes Dev. 2017 Jul 15;31(14):1439-1455
pubmed: 28827399
Exp Ther Med. 2019 Sep;18(3):2332-2340
pubmed: 31452716
EBioMedicine. 2019 Oct;48:36-48
pubmed: 31631037
Biosci Rep. 2019 Aug 13;39(8):
pubmed: 31270250
Ann Oncol. 2009 May;20 Suppl 4:126-8
pubmed: 19454432
Development. 1994 Jul;120(7):2003-14
pubmed: 7925005
Jpn J Clin Oncol. 2015 Feb;45(2):176-82
pubmed: 25378651
Cancer Manag Res. 2019 Jul 24;11:6829-6840
pubmed: 31440081
Oncol Rep. 2019 Nov;42(5):1957-1971
pubmed: 31432186
Curr Opin Oncol. 2016 Nov;28(6):494-501
pubmed: 27606698
Biochem Cell Biol. 2020 Apr;98(2):227-237
pubmed: 31600451
J Exp Clin Cancer Res. 2019 Aug 16;38(1):358
pubmed: 31419987
Clin Exp Metastasis. 2015 Jun;32(5):467-78
pubmed: 25924802
Elife. 2015 Aug 12;4:
pubmed: 26267216

Auteurs

Xiaohe Xu (X)

Department of Ophthalmology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning, P.R. China.

Yunchao Ban (Y)

Department of Neurosurgery, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning, P.R. China.

Zilong Zhao (Z)

Department of Neurosurgery, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning, P.R. China.

Qichen Pan (Q)

Department of Neurosurgery, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning, P.R. China.

Jingyu Zou (J)

Department of Neurosurgery, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning, P.R. China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH